⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 26, 2024Clinical Cancer ResearchOpen Access

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Timothy A. Yap Anthony W. Tolcher Ruth Plummer Jatinder Kaur Mukker Marta Enderlin Christine Hicking Thomas Grombacher Giuseppe Locatelli Zoltán Szűcs Ioannis Gounaris Johann S. de Bono

View Full Paper

Ask AI

Bookmark

Share

Abstract

Tuvusertib (M1774) is a potent, selective, orally administered ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study (NCT04170153) evaluated safety, tolerability, maximum tolerated dose (MTD), recommended dose for expansion (RDE), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of tuvusertib monotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yap et al. (2024) studied this question.

synapsesocial.com/papers/68e777acb6db6435876eca34 https://doi.org/10.1158/1078-0432.ccr-23-2409

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
2Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
3Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
4Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
5Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024